Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.


May 30, 2025
PresentationFiclatuzumab

FIERCE-HN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab (HGF/c-MET MAb) in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

October 15, 2024
PublicationFiclatuzumab

Advanced Human Papillomavirus–Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies

Authors: Robin Park, Christine H. Chung. Click here for link to article.

November 1, 2023
PresentationFiclatuzumab

SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

March 28, 2023
PublicationFiclatuzumab

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

Authors: Julie E. Bauman, Nabil F. Saba, Denise Roe, Jessica R. Bauman, John Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, Shethal Bearelly, Audrey Baker, Conor Steuer, Anshu Giri, Barbara Burtness, Sara Centuori, Carlos Caulin, Robert Klein, Kathylynn Saboda, Stefanie Obara, Christine H. Chung. Click here for link to article.

September 1, 2021
PublicationFiclatuzumab

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

Authors: Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C. Logan, Matthew Settles, Gabriel N. Mannis, Rebecca Olin, Lloyd E. Damon, Thomas G. Martin, Peter H. Sayre, Karin M. Gaensler, Emma McMahon, Michael Flanders, Vivian Weinberg, Chun J. Ye, David P. Carbone, Pamela N. Munster, Gabriela K. Fragiadakis, Frank McCormick, Charalambos Andreadis. Click here for link to article.

June 4, 2021
PresentationFiclatuzumab

ASCO 2021: Randomized Phase II Trial of Ficlatuzumab with or without Cetuximab in Pan-Refractory, Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)